


University of Florida Continuing Medical Education and the Department of Neurosurgery

is honored to present



Maryam Rahman, MD, MD, FAANS

Assistant Professor

Lillian S. Wells Department of Neurosurgery

UF Brain Tumor Immunotherapy Program

UF Health Shands Hospital

“Immunotherapy for GBM”

Release Date: July 1, 2020 Expiration Date: June 30, 2022

Online Registration: neurosurgery.ufl.edu/braincme/

Learning Objectives:

1. Participants will be able to describe immunotherapies for GBM.
2. Participants will be able to understand which immunotherapies have been tested in patients with GBM.
3. Participants will be able to describe how immunomodulation can be leveraged in the treatment of GBM.

Target Audience:

This lecture is attended for primary care physicians, specialty physicians, physician assistants and nurses.

Accreditation:

The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit:

The University of Florida College of Medicine designates this enduring material for a maximum of .25 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Planning Committee Disclosure:

Conflict of interest information for the CME Advisory Committee members can be found on the following website: <https://cme.ufl.edu/disclosure/>.

Faculty Disclosure:

Dr. Rahman has disclosed that she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.

Bibliographic Sources:

Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O'Rourke, D. M., Wong, M., Hamilton, M. G., Finocchiaro, G., Perry, J., Wick, W., Green, J., He, Y., Turner, C. D., ... ACT IV trial investigators (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. *The Lancet. Oncology*, 18(10), 1373–1385. [https://doi.org/10.1016/S1470-2045\(17\)30517-X](https://doi.org/10.1016/S1470-2045(17)30517-X)

Dastmalchi, F., Karachi, A., Yang, C. et al. Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling. *J. Immunotherapy Cancer* 7, 321 (2019). <https://doi.org/10.1186/s40425-019-0809-4>